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Digital Health Passes in the Age of COVID-19
Are “Vaccine Passports” Lawful and Ethical?
As COVID-19 vaccination rates in high-income countries
increase,governmentsareproposingorimplementingdigi-
tal health passes (DHPs) (vaccine “passports” or “certifi-
cates”). Israel uses a “green pass” smartphone application
permitting vaccinated individuals’ access to public venues
(eg, gyms, hotels, entertainment).1 The European Union
plansa“DigitalGreenCertificate”enablingfreetravelwithin
the bloc (see eTable in the Supplement). New York is pi-
loting an IBM “Excelsior Pass,” confirming vaccination
or negative SARS-CoV-2 test status through confidential
data transfers to fast-track business reopenings.2 This
Viewpoint examines the benefits of DHPs, scientific chal-
lenges, and whether they are lawful and ethical.
Benefits of DHPs
Digital health passes offer health and economic benefits
until herd immunity is achieved. By allowing a safe re-
turn to more normal life, DHPs encourage people to be
vaccinated. Digital health passes also allow a gradual re-
opening of the economy in key sectors such as food, retail,
entertainment, and travel. Consumers are likely to rejoin
recreational and commercial activities if they are confident
doing so is safe. Digital health passes offer a less restrictive
means to relax COVID-19 preventive measures such as
quarantines, business closures, and stay-at-home orders.
Scientific and Technical Challenges
Digital health passes involve considerable scientific and
technical challenges, including variable effectiveness by
vaccine type, effectiveness in preventing transmission, du-
rability of immunity, and emergence of variant strains. Cur-
rently, the overall efficacy of 6 SARS-CoV-2 vaccines,
mRNA-1273 (Moderna/NIAID), BNT162b2 (Pfizer-
BioNTech), Ad26.COV2.S (Janssen/Johnson & Johnson),
ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca),
Gam-COVID-Vac/Sputnik V (Gamaleya Research Insti-
tute of Epidemiology and Microbiology), and BBIBP-CorV
(Sinopharm/Beijing Institute of Biological Products), au-
thorized for use in select countries, ranges from 65.5% to
94.6% in preventing symptomatic COVID-19 based on
published clinical trial data. Each vaccine could have vari-
able effectiveness against currently circulating and fu-
ture SARS-CoV-2 variants. Considerable variability in vac-
cine effectiveness in preventing symptomatic disease
could affect the usefulness of DHPs. If DHPs were limited
to only certain vaccine products, it would also exacer-
bate inequities based on access to particular vaccines.
The duration of protection afforded by SARS-
CoV-2 vaccines is uncertain. Coronavirus infections, such
as from the 2002-2004 SARS-CoV-1 outbreak, gener-
ally afford limited protection for 1 to 2 years.3 Reinfec-
tion with SARS-CoV-2 has occurred, albeit rarely. Yet
there is limited evidence of vaccine-induced immunity
beyond limited follow-up of clinical trial participants.
Waning vaccine immunity will be better understood with
follow-up of clinical trial participants, along with obser-
vational studies. Digital health passes should include
dates of series completion to determine expiration once
longevity of vaccine protection is better defined.
Scientific uncertainty also exists about the extent to
which vaccines prevent acquisition and transmission of
SARS-CoV-2. Emerging evidence suggests that vac-
cines significantly reduce asymptomatic infection and
spread.4 Nonpharmaceutical interventions should con-
tinue until herd immunity is achieved.
Digital health passes also involve technical challenges,
includingauthenticationofvaccinestatus.Unlikemosthigh-
income countries, the US has no national immunization in-
formation system (IIS), a confidential, secure, population-
baseddigitaldatabasethatrecordsallvaccinedoses.States
administer IISs, with variable quality. Vaccination facilities
mustreportvaccineadministrationtotherelevantIISwithin
72 hours. Preventing falsification of vaccine status is vital
to DHP integrity. School programs already systematically
authenticate and enforce immunization status through
standardized forms. Companies are also developing tech-




tion status while requiring proof of vaccination for access
tocertainprivileges.Internationallawposesfewrestrictions
on DHPs. The International Health Regulations, signed by
196 countries, grant wide discretion to exercise evidence-
based public health powers. Article 31 of these regulations
specifically allows governments to require “proof of vacci-
nation or other prophylaxis,” while Annex 7 authorizes yel-
low fever vaccination certificates for international travel.
In the US, individual states hold primary public
health powers. States already condition school entry on
proof of vaccination. During the COVID-19 pandemic,
states and localities have also required masks and so-
cial distancing in certain venues. They similarly could au-
thorize or require DHPs, authenticating vaccination sta-
tus either through public or private digital platforms.
The president has broad power to require vaccina-
tion for entry to airports and federal buildings and land,
just as President Biden did for masks. However, a fed-
eral DHP system would likely require congressional ac-
tion, and clear necessity to prevent the interstate spread
of infectious diseases. Congress could also allocate fund-
ing for state DHPs, even conditioning further COVID-19
relief spending on state adoption of DHPs.
Government DHPs must navigate constitutional and
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public health agencies wide discretion, it is more protective of First
Amendment freedoms, including religion, speech, and assembly. The
Court has struck down COVID-19 public gathering restrictions as ap-
plied to houses of worship. The Court would likely subject govern-
ment-run DHPs to high-level scrutiny if they prevented unvacci-
nated individuals from attending religious services or infringed other
constitutionally protected rights.
Private-Sector DHPs
The private sector has a particular interest in ensuring that employ-
ees and customers are vaccinated because it facilitates a return to
social and commercial activities. Businesses could rely on govern-
ment-run or proprietary DHPs. The Equal Employment Opportu-
nity Commission (EEOC) issued guidance on SARS-CoV-2 vaccina-
tions, which applies to any vaccine “approved or authorized by the
Food and Drug Administration,” suggesting that employers could re-
quire vaccinations even under an Emergency Use Authorization.
The EEOC allows employers to require SARS-CoV-2 vaccina-
tion to return to the workplace, thus ensuring employees do “not
pose a direct threat to health or safety.”5 Employers also can use DHPs
for proof of vaccination. Businesses can require employees to “pro-
vide proof they have received a COVID-19 vaccination.” Requiring
proof of vaccination, moreover, does not violate the Americans With
Disabilities Act or the Genetic Information Nondiscrimination Act.
However, employers should caution employees “not to provide any
medical information as part of the proof.”
Digital health passes also would be unlikely to violate privacy
laws, including the Health Insurance Portability and Accountability
Act (HIPAA). Employers typically are not “covered entities” under
HIPAA. Digital health passes could actually be advantageous be-
cause they provide proof of vaccination without sharing any other
medical information.
Although employers may require proof of vaccination, they must
abide by civil rights law. Thus, employers, whenever possible, should
afford persons with disabilities “reasonable accommodations,” such
as through telework. Similarly, employers should provide reason-
able accommodations to individuals who hold a “sincere religious
belief, practice, or observance.” Some states are considering pro-
hibiting private-sector use of DHPs, but courts may decide whether
they have the legal authority to do so.
Ethics and Equity
As long as there is supply scarcity, DHPs would unfairly exclude in-
dividuals who cannot access vaccines. Yet once everyone can gain
access to vaccines, there is a strong ethical justification for DHPs de-
signed to create safer environments to work, shop, recreate, and
travel, as they represent a less restrictive alternative to current pub-
lic health measures.6 Unvaccinated individuals have no right to im-
pose risks on others, thus impeding a return to normal activities. Digi-
tal health passes therefore must be fully and equally available to all
members of society, including the most disadvantaged people. In-
dividuals who cannot be vaccinated for medical reasons also should
not be excluded from DHP privileges. Consideration should also be
given to granting exemptions for genuine religious or conscien-
tious objections.
Health disparities based on race have been a persistent chal-
lenge. Black and Hispanic individuals in the US have had signifi-
cantly lower uptake of SARS-CoV-2 vaccines compared with the over-
all population.7 Racial minorities’ historic distrust of the health system
should not disqualify them from economic and social opportuni-
ties. Governments should amply fund community-based outreach
to encourage vaccine uptake.
Governments or airlines could soon introduce “vaccine pass-
ports” to facilitate international travel. Yet requiring proof of vacci-
nation as a condition of travel would unfairly burden most low- and
middle-income countries, which may lack adequate doses to fully
vaccinate their populations for several years. Approximately 70 coun-
tries have not even begun vaccination campaigns, including most
sub-Saharan African nations. COVAX, the global vaccine facility, aims
to vaccinate only 20% of lower-income populations by 2022. Com-
pounding the unfairness, high-income countries have contributed
to supply scarcity by signing advance purchase agreements with vac-
cine companies. High-income countries could help ameliorate in-
equities through funding and donating vaccine doses to COVAX while
building manufacturing capacities in low- and middle-income coun-
tries, including technology transfer.8
Digital health passes could become an important vehicle for a
rapid return to commerce, recreation, and travel. To ensure their suc-
cess, they must be scientifically well grounded and the least restric-
tive alternative. Above all, DHPs must be administered equitably, en-
suring that everyone has a fair chance to return to a normal life.
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